Vontobel Holding Ltd. Has $780,000 Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Vontobel Holding Ltd. grew its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 137.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 938,295 shares of the biotechnology company's stock after acquiring an additional 543,469 shares during the quarter. Vontobel Holding Ltd. owned about 0.55% of Seres Therapeutics worth $780,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of MCRB. Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 42.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock valued at $708,000 after purchasing an additional 222,771 shares during the last quarter. FMR LLC raised its holdings in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock valued at $21,625,000 after buying an additional 140,096 shares during the last quarter. Providence Wealth Advisors LLC boosted its position in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after buying an additional 22,250 shares during the period. State Street Corp grew its holdings in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after buying an additional 43,700 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock worth $1,314,000 after buying an additional 255,014 shares in the last quarter. Institutional investors own 59.34% of the company's stock.

Seres Therapeutics Price Performance

Shares of MCRB traded down $0.01 during midday trading on Friday, reaching $0.80. The stock had a trading volume of 907,838 shares, compared to its average volume of 1,643,387. The company has a market capitalization of $137.19 million, a P/E ratio of -3.49 and a beta of 2.11. The firm's 50 day moving average price is $0.84 and its 200-day moving average price is $0.85. Seres Therapeutics, Inc. has a 52 week low of $0.54 and a 52 week high of $1.53.

Analyst Ratings Changes

A number of brokerages have issued reports on MCRB. JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Thursday, October 24th. Canaccord Genuity Group restated a "buy" rating and set a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. StockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, February 14th. Finally, Chardan Capital restated a "buy" rating and set a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Seres Therapeutics has an average rating of "Hold" and an average price target of $5.08.

Seres Therapeutics Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.